Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis

G. Girolomoni, G. A. Vena, F. Ayala, S. P. Cannavò, O. De Pità, S. Chimenti, A. Peserico

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Calcipotriol, a vitamin D analogue, and betamethasone dipropionate, a high potency corticosteroid, are complementary agents for the topical treatment of psoriasis vulgaris. Robust evidence on the efficacy and safety of their fixed combination has been provided by randomized, double-blind, controlled clinical trials involving more than 7000 patients with the ointment formulation in psoriasis of the body and more than 4000 patients with the gel formulation in scalp psoriasis. These trials have shown that the fixed combination ointment is more effective and better tolerated, not only than placebo, but also than calcipotriol and tacalcitol monotherapies. In addition, it has proved, in most instances, to be more effective than betamethasone and at least as well tolerated. The same applies to the gel for scalp and body psoriasis. Safety studies have excluded that repeated courses of treatment with the fixed combination for up to one year produce systemic effects. Studies have also shown that the fixed combination treatment improves quality of life to a significantly greater extent than calcipotriol, with the once daily regimen most appreciated by patients, in both active disease and recurrency. Because of the extensive evidence, American and European guidelines recommend the calcipotriol/betamethasone dipropionate fixed combination as first line topical treatment for mild to moderate plaque psoriasis of the body and scalp.

Original languageEnglish
Pages (from-to)609-624
Number of pages16
JournalGiornale Italiano di Dermatologia e Venereologia
Volume147
Issue number6
Publication statusPublished - 2012

Fingerprint

Psoriasis
Scalp
Ointments
Gels
Therapeutics
Safety
Betamethasone
Controlled Clinical Trials
Vitamin D
Adrenal Cortex Hormones
Placebos
Quality of Life
calcipotriene
betamethasone-17,21-dipropionate
Guidelines

Keywords

  • Betamethasone
  • Psoriasis
  • Skin diseases
  • Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Girolomoni, G., Vena, G. A., Ayala, F., Cannavò, S. P., De Pità, O., Chimenti, S., & Peserico, A. (2012). Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis. Giornale Italiano di Dermatologia e Venereologia, 147(6), 609-624.

Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis. / Girolomoni, G.; Vena, G. A.; Ayala, F.; Cannavò, S. P.; De Pità, O.; Chimenti, S.; Peserico, A.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 147, No. 6, 2012, p. 609-624.

Research output: Contribution to journalArticle

Girolomoni, G, Vena, GA, Ayala, F, Cannavò, SP, De Pità, O, Chimenti, S & Peserico, A 2012, 'Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis', Giornale Italiano di Dermatologia e Venereologia, vol. 147, no. 6, pp. 609-624.
Girolomoni, G. ; Vena, G. A. ; Ayala, F. ; Cannavò, S. P. ; De Pità, O. ; Chimenti, S. ; Peserico, A. / Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis. In: Giornale Italiano di Dermatologia e Venereologia. 2012 ; Vol. 147, No. 6. pp. 609-624.
@article{7cd8f342ee55431da5139dc7d36cb84e,
title = "Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis",
abstract = "Calcipotriol, a vitamin D analogue, and betamethasone dipropionate, a high potency corticosteroid, are complementary agents for the topical treatment of psoriasis vulgaris. Robust evidence on the efficacy and safety of their fixed combination has been provided by randomized, double-blind, controlled clinical trials involving more than 7000 patients with the ointment formulation in psoriasis of the body and more than 4000 patients with the gel formulation in scalp psoriasis. These trials have shown that the fixed combination ointment is more effective and better tolerated, not only than placebo, but also than calcipotriol and tacalcitol monotherapies. In addition, it has proved, in most instances, to be more effective than betamethasone and at least as well tolerated. The same applies to the gel for scalp and body psoriasis. Safety studies have excluded that repeated courses of treatment with the fixed combination for up to one year produce systemic effects. Studies have also shown that the fixed combination treatment improves quality of life to a significantly greater extent than calcipotriol, with the once daily regimen most appreciated by patients, in both active disease and recurrency. Because of the extensive evidence, American and European guidelines recommend the calcipotriol/betamethasone dipropionate fixed combination as first line topical treatment for mild to moderate plaque psoriasis of the body and scalp.",
keywords = "Betamethasone, Psoriasis, Skin diseases, Therapeutics",
author = "G. Girolomoni and Vena, {G. A.} and F. Ayala and Cannav{\`o}, {S. P.} and {De Pit{\`a}}, O. and S. Chimenti and A. Peserico",
year = "2012",
language = "English",
volume = "147",
pages = "609--624",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "6",

}

TY - JOUR

T1 - Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis

AU - Girolomoni, G.

AU - Vena, G. A.

AU - Ayala, F.

AU - Cannavò, S. P.

AU - De Pità, O.

AU - Chimenti, S.

AU - Peserico, A.

PY - 2012

Y1 - 2012

N2 - Calcipotriol, a vitamin D analogue, and betamethasone dipropionate, a high potency corticosteroid, are complementary agents for the topical treatment of psoriasis vulgaris. Robust evidence on the efficacy and safety of their fixed combination has been provided by randomized, double-blind, controlled clinical trials involving more than 7000 patients with the ointment formulation in psoriasis of the body and more than 4000 patients with the gel formulation in scalp psoriasis. These trials have shown that the fixed combination ointment is more effective and better tolerated, not only than placebo, but also than calcipotriol and tacalcitol monotherapies. In addition, it has proved, in most instances, to be more effective than betamethasone and at least as well tolerated. The same applies to the gel for scalp and body psoriasis. Safety studies have excluded that repeated courses of treatment with the fixed combination for up to one year produce systemic effects. Studies have also shown that the fixed combination treatment improves quality of life to a significantly greater extent than calcipotriol, with the once daily regimen most appreciated by patients, in both active disease and recurrency. Because of the extensive evidence, American and European guidelines recommend the calcipotriol/betamethasone dipropionate fixed combination as first line topical treatment for mild to moderate plaque psoriasis of the body and scalp.

AB - Calcipotriol, a vitamin D analogue, and betamethasone dipropionate, a high potency corticosteroid, are complementary agents for the topical treatment of psoriasis vulgaris. Robust evidence on the efficacy and safety of their fixed combination has been provided by randomized, double-blind, controlled clinical trials involving more than 7000 patients with the ointment formulation in psoriasis of the body and more than 4000 patients with the gel formulation in scalp psoriasis. These trials have shown that the fixed combination ointment is more effective and better tolerated, not only than placebo, but also than calcipotriol and tacalcitol monotherapies. In addition, it has proved, in most instances, to be more effective than betamethasone and at least as well tolerated. The same applies to the gel for scalp and body psoriasis. Safety studies have excluded that repeated courses of treatment with the fixed combination for up to one year produce systemic effects. Studies have also shown that the fixed combination treatment improves quality of life to a significantly greater extent than calcipotriol, with the once daily regimen most appreciated by patients, in both active disease and recurrency. Because of the extensive evidence, American and European guidelines recommend the calcipotriol/betamethasone dipropionate fixed combination as first line topical treatment for mild to moderate plaque psoriasis of the body and scalp.

KW - Betamethasone

KW - Psoriasis

KW - Skin diseases

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84874364947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874364947&partnerID=8YFLogxK

M3 - Article

C2 - 23149707

AN - SCOPUS:84874364947

VL - 147

SP - 609

EP - 624

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 6

ER -